The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes rejected bid of 28p a few weeks ago
18 July 2019
NAHL Group PLC
Pre-Close Trading Update
NAHL (AIM: NAH), the leading UK marketing and services business focused on the UK consumer legal market, is today providing a trading update for the first half of its current financial year, covering the six months to 30 June 2019.
The Group has performed in line with the Board's underlying earnings* expectations, with revenue and underlying operating profit** both showing growth against the same period last year, as well as sequential growth on H2 2018. Net debt at 30 June 2019 was GBP17.6m, which was marginally lower than the Board's expectations.
Within the Group's Personal Injury division ("PI"), National Accident Helpline ("NAH") continues to operate in challenging market conditions, driven by competitive pressures. The Board expects these to persist until the implementation date of the legal reforms, currently planned for April 2020. NAH management continue to adapt the division's marketing and placement tactics to respond and optimise the results. The strategic transformation of PI continues and, pleasingly, the contribution from its Legal Services business unit is slightly ahead of expectations. This includes the Group's wholly owned law firm, National Accident Law, which has made encouraging progress since its launch in April 2019.
The Group's Critical Care division has performed in line with the Board's expectations and delivered double digit profit growth in H1 2019.
Whilst the residential property market has deteriorated further in H1, we have continued to progress a number of initiatives to drive growth in H2 and are beginning to see some market share gains.
Overall, despite no noticeable improvement in market conditions, the Board is pleased with the Group's strategic progress and its underlying earnings* expectations for the full year remain unchanged.
NAHL will announce its results for the six months ended 30 June 2019 on 17 September 2019.
Russell Atkinson, CEO of NAHL, commented:
"The first half of 2019 has been an exciting period with the successful launch of the Group's wholly owned law firm, National Accident Law, which has demonstrated encouraging progress. Critical Care has continued to perform well, generating a strong profit performance, while the Residential Property team have concentrated on driving share growth in a difficult market environment.
"The Board is pleased with the Group's performance during the first half and remains excited about the opportunity that National Accident Law represents for the PI
Here it is
Hemogenyx Pharmaceuticals PLC CDX Effective as Conditioning Therapeutic in vivo
12/06/2019 7:00am
Hemogenyx Pharmaceuticals (LSE:HEMO)
Intraday Stock Chart
Today : Wednesday 12 June 2019
Hemogenyx Pharmaceuticals PLC
12 June 2019
Hemogenyx Pharmaceuticals plc
CDX Antibody is Effective as Conditioning Therapeutic in vivo
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces further progress with its original core development: the use of a CDX bi-specific antibody ("CDX antibody") product candidate as a conditioning therapy for bone marrow transplants. The Company has obtained the first data results from in vivo testing of its CDX antibody developed in collaboration with a global pharmaceutical company under the partnership previously announced by the Company on 14 May 2018.
The first data results demonstrate that the CDX antibody is capable of eliminating human hematopoietic stem cells/hematopoietic progenitors ("HSC"/"HP" aka blood stem cells) in vivo. The Company verified the efficacy of CDX as a conditioning therapeutic using its proprietary advanced hematopoietic chimeric ("AHC") mice (humanised mice).
The CDX antibody was shown to target blood stem cells that express the protein FLT3. The CDX antibody binds to the FLT3 protein that is located on the surface of unwanted (target) cells and also binds to the CD3 protein on the surface of T-cells, and ultimately redirects T-cells to kill the target cells.
Vladislav Sandler, Chief Executive Officer, commented, "This new data demonstrates our continuing progress in developing potential uses for our CDX antibody. Our new data demonstrates the efficacy of the CDX antibody as a conditioning therapeutic when tested in vivo in our own proprietary advanced humanised mouse model which closely replicates the human immune system. We are much encouraged by this new data, and we will endeavor to keep shareholders informed of further progress as it occurs."
A bit of upward movement Friday let us see what next week brings
Hemogenyx Pharmaceuticals PLC CDX Antibody is Effective against ALL in vitro
30/05/2019 7:00am
Hemogenyx Pharmaceuticals (LSE:HEMO)
Intraday Stock Chart
Today : Thursday 30 May 2019
30 May 2019
("Hemogenyx" or the "Company")
CDX Antibody is Effective against ALL in vitro
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces the first data results from in vitro testing of its CDX bi-specific antibody ("CDX antibody") product candidate for the treatment of Acute Lymphoblastic Leukemia ("ALL"), a form of blood cancer. The first data results demonstrate that the CDX antibody is capable of eliminating a subset of ALL cells in vitro. The CDX antibody was shown to target ALL cells that contain mixed-lineage leukemia 1 (MLL1) gene rearrangements and overexpress the protein FLT3. CDX binds to the FLT3 protein that is located on the surface of unwanted (target) cells, binds to the CD3 protein on the surface of T-cells, and ultimately redirects T-cells to kill the target cells. The Company is planning to verify the efficacy of CDX against ALL in vivo in the near future, using its proprietary advanced hematopoietic chimeric ("AHC") mice and similar testing to that which the Company used to demonstrate the efficacy of CDX against AML.
Vladislav Sandler, Chief Executive Officer, commented, "We are encouraged by this new data which demonstrates our continuing progress in the development and potential uses of our CDX antibody and the widening range of conditions to which it may be applicable. We previously demonstrated that CDX antibody may be effective in treating acute myeloid leukemia ("AML"), another type of aggressive blood cancer. This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor."
Director buys over £320.000 grands worth
The Company announces that it received notification on 23 May 2019 that the following Directors have each purchased Ordinary Shares of 27 2/7 pence each in the Company ("Shares").
John Barton, Chairman, acquired 11,000 Shares at a price of GBP9.024 per share. Johan Lundgren, Chief Executive Officer, acquired 20,000 Shares at a price of GBP9.066 per share. Andrew Findlay, Chief Financial Officer, acquired 4,500 Shares at a price of GBP9.050 per share. All transactions took place on 23 May 2019 in London.
Maybe time to follow suit
Looks like the next leg could be imminent, ex divi in 4 weeks with profits increasing the divi now looks safe at these levels
* News Release *
Issue Date: 12 March 2019
Redde plc
("Company")
Director/PDMR Shareholding
The Company announces that certain directors and their persons closely
associated ("PCAs") have recently purchased an aggregate of 139,374 ordinary
shares with an aggregate value of GBP122,262 in the Company in the following
amounts:
Name Position Ordinary Price Number of Date of
shares paid per Ordinary purchase
purchased share Shares held
following
the
purchase
Avril Chairwoman 56,497 88.50p 56,497 12-Mar-19
Palmer-Baunack
Martin Ward Chief Executive 56,497 88.50p 3,980,958 12-Mar-19
Officer
Patricia Oakley PCA with Stephen 26,380 84.39p 12-Mar-19
Oakley, Chief 2,020,000
Financial Officer
You are wasting your time they only post when the share price is going down,
Half/year results on Wednesday
Why does anybody engages with the lying jailbird RICH I do not know, let him repeat his repetitive crap to himself
That was some rise yesterday I wonder what was behind it/?
IGAS Energy (LON:IGAS) had its "buy" rating reaffirmed by analysts at Canaccord Genuity ( ). They now have a GBX 250 ($3.27) price target on the stock.
Issue Date: Tuesday 18 December 2018
Redde plc ('Redde' or 'Group')
Trading Update - Growth continues
Current Trading
The Redde Board is pleased to announce that the Group's positive start to the
year that we referred to in our full year results announcement on 6 September
and AGM statement on 24 October 2018 has carried through into December.
Sales again show an increase over the corresponding period last year reflecting
continued growth in trading volumes and as a consequence, trading profits are
ahead of the corresponding period last year.
Results for the 6 months to 31 December 2018
The Board expects to announce the results for the 6 months to 31 December 2018
on Wednesday 27 February 2019.
Should be Monday
It does not matter what trolls and jailbirds value IGAS at what counts is what the market value them at 87.5p at the moment now as with all shares they can go up or down make your own mind up is the answer
Trading update next week should be very positive
Quiet when the share price is up